SLC5A2 and chronic kidney disease: The evidence for applying preventive medical management for CKD progression by adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to the current standard of care (SoC) shows potential for decreasing the clinical and economic burden on the healthcare system.